Ann: CLARITY 2.0 COVID-19 Study Concludes Recruitment, page-43

Hey All,

Clarity 1 results are out. In mild disease with COVID-19 & this was with ARB only, not DMX-200 on top of ARB. So it’s not our trial (Clarity 2.0). Need to read for context.

https://www.bmj.com/content/379/bmj-2022-072175

But as I suspected earlier on, large platform trials such as REMAP CAP & others with NHMRC already involved with, will collaborate on data collected as per WHO standards, which I also suspect will happen with DMX-200 data in hospitalised patients (moderate-severe state). Need to look at demographics of recruitment & all this paper. I’m not put off by this at all in ARB alone in mildly sick patients. No wonder the criteria was changed to hospitalised & requiring O2 for Clarity 2.

Now to look at DXB latest presentation, sounds positive. Thanks for the posts Guys!